Table 1 Baseline characteristics of TILT participants. All values given are n (%) unless otherwise stated

Total

7

1

3

3

Male

6 (85.7)

-

3 (100)

3 (100)

Age, median (range)

73 (60–83)

64

71 (60–73)

80 (73–83)

Performance status

 0

3 (42.9)

-

2 (66.7)

1 (33.3)

 1

2 (28.5)

1 (100)

-

1 (33.3)

 2

1 (14.3)

-

-

1 (33.3)

 3

1 (14.3)

-

1 (33.3)

-

Asbestos exposure

 None recalled

1 (14.3)

1 (100)

-

-

 Transient

1 (14.3)

-

-

1 (33.3)

 Light/passive

1 (14.3)

-

1 (33.3)

-

 Heavy/active

4 (57.1)

-

2 (66.7)

2 (66.7)

Presenting symptoms

 Breathlessness

5 (71.4)

1 (100)

2 (66.7)

2 (66.7)

 Chest pain

1 (14.3)

-

1 (33.3)

-

 Cough

3 (42.9)

-

2 (66.7)

1 (33.3)

 Sweats

-

-

-

-

 Lethargy

1 (14.3)

-

1 (33.3)

-

 Anorexia

1 (14.3)

-

-

1 (33.3)

 Weight loss

1 (14.3)

-

-

1 (33.3)

 Asymptomatic

1 (14.3)

-

-

1 (33.3)

Duration of symptoms

  < 1 month

3 (42.9)

1 (100)

1 (33.3)

1 (33.3)

 1–3 months

1 (14.3)

-

-

1 (33.3)

  > 3 months

2 (28.6)

-

2 (66.7)

-

 Not recorded

1 (14.3)

-

-

1 (33.3)

Method of diagnosis

 CT-guided biopsy

1 (14.3)

1 (100)

-

-

 Medical thoracoscopy

5 (71.4)

-

3 (100)

2 (66.7)

 VATS

1 (4.3)

-

-

1 (33.3)

Laterality

 Left

2 (28.6)

-

1 (33.3)

1 (33.3)

 Right

5 (71.4)

1 (100)

2 (66.7)

2 (66.7)

Tumour histology

 Epithelioid

7 (100)

1 (100)

3 (100)

3 (100)

Previous treatment

 Chemotherapy

1 (100)

1 (100)

-

-

 Radiotherapy

-

-

-

-

 Surgery

-

-

-

-

 Bevacizumab

-

-

-

-

 Immunotherapy

-

-

-

-

Brims prognostic score

 1 (best prognosis)

1 (14.3)

-

-

1 (33.3)

 2

5 (71.4)

1 (100)

3 (100)

1 (33.3)

 3

-

-

-

-

 4 (worst prognosis)

1 (14.3)

-

-

1 (33.3)